Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

CME Outfitters

Improving the Quality of Care for Patients with Atopic Dermatitis: Integrating Measurement-Based Tools Into Your Clinical Practice

Access Activity

Overview / Abstract:

Statement of Need
Attitudes about atopic dermatitis are evolving with the emergence of new and effective treatments. With the average dermatologist having not enjoyed caring for patients with AD for decades, there is little to no consensus in current practice about validated tools to assess and monitor the severity of the diseases and no consistent use of diagnostic or assessment tools. This lack of knowledge and education leads to confusion, poor recognition, and absence of assessment of AD severity.

The use of patient-reported outcomes such as the Patient-Oriented Eczema Measure (POEM) are often underused in clinical practice despite being simple, valid, repeatable, and easy to interpret. The use of tools such as POEM is important to capture the impact of AD on health-related quality of life.

In this CME Outfitters On Demand webcast, expert faculty will discuss diagnostic assessment and measurement of symptom severity in AD including patient-reported outcomes, with the goal of educating clinicians regarding tools for diagnosis and assessment that can be integrated into their clinical practice.

Learning Objectives

At the end of this CE activity, participants should be able to:
- Apply the Hanifin Rajka criteria and/or the American Academy of Dermatology (AAD) criteria to facilitate the diagnosis of AD in clinical practice
- Incorporate the POEM assessment scale into clinical practice to monitor disease severity and response to treatment.
- Document the utilization of clinical assessment tools and results form their use in patients' charts.

The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize the Hanifin Rajka criteria and/or the American Academy of Dermatology (AAD) criteria used to diagnose AD.
- Describe the POEM assessment scale for monitoring disease severity and response to treatment.
- Identify the tools and clinical assessment results that should be documented in patients' charts.


Dec 31, 2020


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Online, Podcast, Webinar / Webcast / Video

Credits / Hours

1.5 AMA PRA Category 1 Credit(s)™



Presenters / Authors / Faculty

Zelma C. Chiesa Fuxench, MD, MSCE
Assistant Professor of Dermatology
Department of Dermatology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Stephen D. Hess, MD, PhD
President / Medical Director
Center City Dermatology
Clinical Associate in Dermatology
Department of Dermatology
Hospital of the University of Pennsylvania
Philadelphia, PA

John J. Russell, MD
Clinical Professor of Family and Community Medicine
Sydney Kimmel Medical College
Thomas Jefferson University School of Medicine
Philadelphia, PA
Program Director
Family Medicine Residency Program
Abington Hospital - Jefferson Health
Abington, PA

Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor of Dermatology, Medical Social Sciences and Preventive Medicine
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Contact Dermatitis Clinic, Northwestern Memorial Hospital
Chicago, IL

Sponsors / Supporters / Grant Providers

Supported by an educational grant form Sanofi Genzyme and Regeneron Pharmaceuticals.

Keywords / Search Terms

CME Outfitters atopic dermatitis, dermatitis, dermatology, dermatologist, derm, skin, psoriasis, eczema, AAD, patient care, Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.